Literature DB >> 27379869

Chromatin Landscape of the IRF Genes and Role of the Epigenetic Reader BRD4.

Mahesh Bachu1, Anup Dey1, Keiko Ozato1.   

Abstract

Histone post-translational modification patterns represent epigenetic states of genomic genes and denote the state of their transcription, past history, and future potential in gene expression. Genome-wide chromatin modification patterns reported from various laboratories are assembled in the ENCODE database, providing a fertile ground for understanding epigenetic regulation of any genes of interest across many cell types. The IRF family genes critically control innate immunity as they direct expression and activities of interferons. While these genes have similar structural and functional traits, their chromatin landscapes and epigenetic features have not been systematically evaluated. Here, by mining ENCODE database using an imputational approach, we summarize chromatin modification patterns for 6 of 9 IRF genes and show characteristic features that connote their epigenetic states. BRD4 is a BET bromodomain protein that "reads and translates" epigenetic marks into transcription. We review recent findings that BRD4 controls constitutive and signal-dependent transcription of many genes, including IRF genes. BRD4 dynamically binds to various genomic genes with a spatial and temporal specificity. Of particular importance, BRD4 is shown to critically regulate IRF-dependent anti-pathogen protection, inflammatory responses triggered by NF-κB, and the growth and spread of many cancers. The advent of small molecule inhibitors that disrupt binding of BET bromdomain to acetylated histone marks has opened new therapeutic possibilities for cancer and inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27379869      PMCID: PMC4931755          DOI: 10.1089/jir.2015.0179

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  45 in total

1.  A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition.

Authors:  A Dey; J Ellenberg; A Farina; A E Coleman; T Maruyama; S Sciortino; J Lippincott-Schwartz; K Ozato
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae.

Authors:  Masaki Yamashita; Minoru Toyota; Hiromu Suzuki; Masanori Nojima; Eiichiro Yamamoto; Seiko Kamimae; Yoshiyuki Watanabe; Masahiro Kai; Hirofumi Akashi; Reo Maruyama; Yasushi Sasaki; Hiroo Yamano; Tamotsu Sugai; Yasuhisa Shinomura; Kohzoh Imai; Takashi Tokino; Fumio Itoh
Journal:  Cancer Sci       Date:  2010-04-02       Impact factor: 6.716

3.  Combinatorial patterns of histone acetylations and methylations in the human genome.

Authors:  Zhibin Wang; Chongzhi Zang; Jeffrey A Rosenfeld; Dustin E Schones; Artem Barski; Suresh Cuddapah; Kairong Cui; Tae-Young Roh; Weiqun Peng; Michael Q Zhang; Keji Zhao
Journal:  Nat Genet       Date:  2008-06-15       Impact factor: 38.330

4.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

Review 5.  Mechanism and function of oxidative reversal of DNA and RNA methylation.

Authors:  Li Shen; Chun-Xiao Song; Chuan He; Yi Zhang
Journal:  Annu Rev Biochem       Date:  2014       Impact factor: 23.643

6.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

7.  Control of inducible gene expression by signal-dependent transcriptional elongation.

Authors:  Diana C Hargreaves; Tiffany Horng; Ruslan Medzhitov
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

8.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

9.  A panel of genes methylated with high frequency in colorectal cancer.

Authors:  Susan M Mitchell; Jason P Ross; Horace R Drew; Thu Ho; Glenn S Brown; Neil F W Saunders; Konsta R Duesing; Michael J Buckley; Rob Dunne; Iain Beetson; Keith N Rand; Aidan McEvoy; Melissa L Thomas; Rohan T Baker; David A Wattchow; Graeme P Young; Trevor J Lockett; Susanne K Pedersen; Lawrence C Lapointe; Peter L Molloy
Journal:  BMC Cancer       Date:  2014-01-31       Impact factor: 4.430

10.  Mediator kinase inhibition further activates super-enhancer-associated genes in AML.

Authors:  Henry E Pelish; Brian B Liau; Ioana I Nitulescu; Anupong Tangpeerachaikul; Zachary C Poss; Diogo H Da Silva; Brittany T Caruso; Alexander Arefolov; Olugbeminiyi Fadeyi; Amanda L Christie; Karrie Du; Deepti Banka; Elisabeth V Schneider; Anja Jestel; Ge Zou; Chong Si; Christopher C Ebmeier; Roderick T Bronson; Andrei V Krivtsov; Andrew G Myers; Nancy E Kohl; Andrew L Kung; Scott A Armstrong; Madeleine E Lemieux; Dylan J Taatjes; Matthew D Shair
Journal:  Nature       Date:  2015-09-28       Impact factor: 49.962

View more
  7 in total

1.  Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune Phenotype.

Authors:  Emily Fraser; Laura Denney; Agne Antanaviciute; Karl Blirando; Chaitanya Vuppusetty; Yuejuan Zheng; Emmanouela Repapi; Valentina Iotchkova; Stephen Taylor; Neil Ashley; Victoria St Noble; Rachel Benamore; Rachel Hoyles; Colin Clelland; Joseph M D Rastrick; Clare S Hardman; Nasullah K Alham; Rachel E Rigby; Alison Simmons; Jan Rehwinkel; Ling-Pei Ho
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

2.  Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth.

Authors:  Hua Zhu; Jia-Hui Mao; Yin Wang; Dong-Hua Gu; Xiao-Dong Pan; Yuxi Shan; Bing Zheng
Journal:  Oncotarget       Date:  2017-09-30

3.  The C-Terminal Transactivation Domain of STAT1 Has a Gene-Specific Role in Transactivation and Cofactor Recruitment.

Authors:  Matthias Parrini; Katrin Meissl; Mojoyinola Joanna Ola; Therese Lederer; Ana Puga; Sebastian Wienerroither; Pavel Kovarik; Thomas Decker; Mathias Müller; Birgit Strobl
Journal:  Front Immunol       Date:  2018-12-06       Impact factor: 7.561

4.  ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.

Authors:  Ling He; Chen Chen; Guoyu Gao; Kun Xu; Zhaoqun Ma
Journal:  Aging (Albany NY)       Date:  2020-03-12       Impact factor: 5.682

5.  X chromosome escapee genes are involved in ischemic sexual dimorphism through epigenetic modification of inflammatory signals.

Authors:  Shaohua Qi; Abdullah Al Mamun; Conelius Ngwa; Sharmeen Romana; Rodney Ritzel; Arthur P Arnold; Louise D McCullough; Fudong Liu
Journal:  J Neuroinflammation       Date:  2021-03-12       Impact factor: 8.322

6.  Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.

Authors:  Huan-Tian Zhang; Rui Peng; Sheng Chen; Ao Shen; Lixin Zhao; Wang Tang; Xiao-He Wang; Zhen-Yan Li; Zhen-Gang Zha; Mengmeng Yi; Lingmin Zhang
Journal:  Adv Sci (Weinh)       Date:  2022-08-21       Impact factor: 17.521

7.  N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells.

Authors:  Joshua A Nord; Sarah L Wynia-Smith; Alyssa L Gehant; Rachel A Jones Lipinski; Aaron Naatz; Inmaculada Rioja; Rab K Prinjha; John A Corbett; Brian C Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-13       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.